Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma by Hareth Nahi, Gabriel Afram, Katarina Uttervall, Sandra Lockmer, Love Tätting, Gösta Gahrton, Muhammad Kashif, Evren Alici, Olga Stromberg, Monika Klimkowska, Johan Lund

Subjects: “…minimum residual disease…”
Get full text

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives by Yan Peng, Wuxuan Mei, Kaidong Ma, Changchun Zeng

Subjects: Get full text

Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches by L. Yu. Grivtsova, V. V. Lunin, A. A. Semenova, V. B. Larionova, G. S. Tumyan

Subjects: Get full text

Identification of tumor mutations in plasma based on mutation variant frequency change (MVFC) by Geng Chen, Fang Peng, Xiuqing Dong, Zhixiong Cai, Zhenli Li, Lei He, Jinpan Hu, Xiaoxu Deng, Yutong Guo, Liman Qiu, Yang Zhou, Jingfeng Liu, Huqin Zhang, Xiaolong Liu

Subjects: Get full text

Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease) by Amirhossein Kazemian, Pardis Nematollahi

Subjects: Get full text